Rethinking Heterogeneity in Community-Acquired Pneumonia Care and Outcomes: Mark Metersky, MD

Community-acquired pneumonia (CAP) remains one of the most common causes of hospitalization worldwide, yet clinicians are increasingly recognizing that patient outcomes can vary dramatically depending on both the infecting pathogen and the patient’s underlying biology.

At the American Thoracic Society International Conference 2026 in Orlando, Florida, experts discussed how emerging molecular diagnostics, immune profiling, and precision medicine approaches may help reshape the future of CAP management.

In an interview with The American Journal of Managed Care^®, Mark Metersky, MD, of University of Connecticut Health, discussed the growing need to rethink conventional approaches to pneumonia care.

There are still significant gaps in clinician understanding of why patients experience such different responses to infection and treatment.

“We know that we have a long way to go to understand how different patients respond to different pathogens,” Metersky said.

He continued to explain that outcomes are influenced not only by the infecting organism itself but also by patient-specific factors, including immunosuppression, preexisting pulmonary or cardiac disease, and baseline health status.

Metersky also highlighted the growing recognition of immune dysfunction in CAP and how different immune responses may contribute to worse outcomes in different patient populations.

“Some patients have what’s called immunoparalysis, a severe suppression of their immune system. Other patients have a very hyperdrive setting of their immune system that causes harm,” he said.

Additionally, he emphasized the role of rapidly evolving molecular diagnostics in advancing more individualized approaches to pneumonia care. Historically, clinicians lacked the tools needed to rapidly identify pathogens or differentiate patient subgroups in a meaningful way. However, newer molecular methods can now identify viruses, bacteria, and even resistance genes much faster than traditional testing methods.

Looking ahead, Metersky said he believes these advances may eventually translate into more personalized bedside care, predicting that within the next “5 to 7 years,” clinicians could begin applying these insights more directly in clinical practice.